A Phase 3 interventional study of bexarotene with carboplatin and paclitaxel and carboplatin and paclitaxel in Non-small Cell Lung Cancer, sponsored by Eisai Inc.. Completed at 154 sites in 6 countries. Per ClinicalTrials.gov, last updated 2012-07-13.
Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 272 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 40 under way, 12 of them phase 3. Carboplatin · Carcinoma, Non-Small-Cell Lung.
Among the 272 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung, this one is the 11th largest by enrollment of the 251 interventional ones that give a count, is one of 16 that started in 2002, is one of 47 in phase 3, and was the 44th registered.
7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →22 of the 272 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
Swiss Cancer Institute · Sites in Switzerland
Ages 70+
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
People's Hospital of Quzhou · Sites in China
Ages 18–75
Latin American Cooperative Oncology Group · Sites in Brazil
Ages 18+
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–85
By country, each count listing its studies:
Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
272 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 66 · Phase 2 177 · Phase 3 50 · Phase 4 3
First in 1996; this study’s year is marked. 16 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 612 is above the median of 62 across 6,031 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 55 across the 251 interventional studies. Of the 188 that completed or were terminated, 78 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
77 of 272 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
15 studies in Carcinoma, Non-Small-Cell Lung by Eisai Co., Ltd.: 1 open now, 1 under way, none of them phase 3. Of 14 finished, 10 (71%) have results posted.
Among the 15 studies in Carcinoma, Non-Small-Cell Lung by Eisai Co., Ltd., this one is the 2nd largest by enrollment, is the only one that started in 2002, is one of 3 in phase 3, and was the 1st registered.
Eisai Co., Ltd.’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2002.
9 of the studies testing carboplatin in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT05654454Phase 3Mabscale, LLCA Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer | 2026-12 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT03965468ETOP IBCSG Partners FoundationImmunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC | 2026-12 |
Add all 9 to your calendar (.ics) → With an account.
Among the 272 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eisai Co., Ltd.’s 15 in Carcinoma, Non-Small-Cell Lung:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluates the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have not yet received chemotherapy for their lung cancer.
This study evaluates the use of Targretin capsules (bexarotene) in combination with Carboplatin and Paclitaxel for the treatment of metastatic non-small cell lung cancer in patients who have not yet received chemotherapy for their lung cancer. Every patient receives a platinum-containing chemotherapy every three weeks for at least four chemotherapy cycles (approximately four months). Half of the patients are randomly assigned to receive Targretin capsules once daily in addition to the chemotherapy. The other half is randomized to receive a standard platinum-containing chemotherapy without Targretin capsules.
Patients must have:
Patients must be able to complete at least four cycles of combination chemotherapy (i.e., approximately four months)
Patients must not have had:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: bexarotene with carboplatin and paclitaxel
Drug: carboplatin and paclitaxel
Drug pages: BexaroteneStudies of BexaroteneBexarotene pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CarboplatinStudies of CarboplatinCarboplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PaclitaxelStudies of PaclitaxelPaclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
bexarotene capsules (400 mg/m\^2/day) in combination with carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m\^2) every 3 weeks. Subjects in this group also received an antilipid agent which was selected at the discretion of the investigator.
Drug pages: CarboplatinStudies of CarboplatinCarboplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PaclitaxelStudies of PaclitaxelPaclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m\^2) every 3 weeks.
Overall Survival
Time frame: From date of randomization to date of death
| Milestone | Bexarotene With Carboplatin and Paclitaxel | Carboplatin and Paclitaxel |
|---|---|---|
| Started | 306 | 306 |
| Completed | 4 | 2 |
| Not completed | 302 | 304 |
| Withdrew: Progressive disease | 137 | 93 |
| Withdrew: Stable disease | 19 | 48 |
| Withdrew: Partial response | 14 | 19 |
| Withdrew: Complete response | 0 | 2 |
| Withdrew: Adverse event | 62 | 61 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 23 | 18 |
| Withdrew: Administrative | 31 | 46 |
| Withdrew: Non-compliance | 3 | 1 |
| Withdrew: Death | 13 | 15 |
| Months | Bexarotene With Carboplatin and Paclitaxel | Carboplatin and Paclitaxel |
|---|---|---|
| Overall Survival | 8.5 (7.7 to 9.3) | 9.2 (8.3 to 10.5) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bexarotene With Carboplatin and Paclitaxel | — | 256/293 (87.4%) | 293/293 (100%) |
| Carboplatin and Paclitaxel | — | 242/295 (82%) | 295/295 (100%) |
| Event | Bexarotene With Carboplatin and Paclitaxel | Carboplatin and Paclitaxel |
|---|---|---|
| Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 219/293 | 213/295 |
| DehydrationMetabolism and nutrition disorders | 19/293 | 7/295 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 18/293 | 11/295 |
| AnaemiaBlood and lymphatic system disorders | 14/293 | 7/295 |
| PyrexiaGeneral disorders | 12/293 | 8/295 |
| Febrile neutropeniaBlood and lymphatic system disorders | 11/293 | 9/295 |
| NeutropeniaBlood and lymphatic system disorders | 11/293 | 2/295 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 10/293 | 8/295 |
| VomitingGastrointestinal disorders | 9/293 | 6/295 |
| AstheniaGeneral disorders | 9/293 | 4/295 |
| Event | Bexarotene With Carboplatin and Paclitaxel | Carboplatin and Paclitaxel |
|---|---|---|
| HypotriglyceridemiaMetabolism and nutrition disorders | 168/293 | 6/295 |
| FatigueGeneral disorders | 156/293 | 137/295 |
| AlopeciaSkin and subcutaneous tissue disorders | 147/293 | 154/295 |
| AnemiaBlood and lymphatic system disorders | 147/293 | 112/295 |
| NauseaGastrointestinal disorders | 147/293 | 140/295 |
| NeutropeniaBlood and lymphatic system disorders | 138/293 | 71/295 |
| DiarrhoeaGastrointestinal disorders | 108/293 | 68/295 |
| VomitingGastrointestinal disorders | 96/293 | 78/295 |
| ConstipationGastrointestinal disorders | 80/293 | 84/295 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 78/293 | 68/295 |
| Age, Categorical(Participants) | Bexarotene With Carboplatin and Paclitaxel | Carboplatin and Paclitaxel | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 166 | 174 | 340 |
| >=65 years | 140 | 132 | 272 |
| Age Continuous(years) | Bexarotene With Carboplatin and Paclitaxel | Carboplatin and Paclitaxel | Total |
|---|---|---|---|
| Mean | 62.5 ± 9.6 | 61.7 ± 10.3 | 62.1 ± 10.0 |
| Sex: Female, Male(Participants) | Bexarotene With Carboplatin and Paclitaxel | Carboplatin and Paclitaxel | Total |
|---|---|---|---|
| Female | 103 | 103 | 206 |
| Male | 203 | 203 | 406 |
| Ethnicity (NIH/OMB)(Participants) | Bexarotene With Carboplatin and Paclitaxel | Carboplatin and Paclitaxel | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 9 | 11 |
| Not Hispanic or Latino | 304 | 297 | 601 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Bexarotene With Carboplatin and Paclitaxel | Carboplatin and Paclitaxel | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 7 | 3 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 23 | 20 | 43 |
| White | 269 | 272 | 541 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 2 | 7 |
Showing the first 100 of 154 sites across 6 countries. Choose a country and city above to see the rest.
The record gives a start of May 2002, a primary completion of Jul 2004 and a completion of Mar 2005. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2010, 6 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bexarotene · Carboplatin · Paclitaxel
Carcinoma, Non-Small-Cell Lung →